Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Christensen

Showing results (481-490 of 510) with videos related to

Pageof 51
Sort By:
Science Translational Medicine|March 25, 2011
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsLecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, et al.
The New England Journal of Medicine|June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Mark M Awad, Ryohei Katayama, Michele McTigue, et al.
Journal of Medicinal Chemistry|January 18, 2022
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i>-Deleted CancersChristopher R Smith, Ruth Aranda, Thomas P Bobinski, et al.
The Journal of Antibiotics|October 10, 1998
Discovery of MC-02,331, a new cephalosporin exhibiting potent activity against methicillin-resistant Staphylococcus aureusS J Hecker, I S Cho, T W Glinka, et al.
Cancer Research|July 28, 2011
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitorsTakaaki Sasaki, Jussi Koivunen, Atsuko Ogino, et al.
The New England Journal of Medicine|June 3, 2022
Adagrasib in Non-Small-Cell Lung Cancer Harboring a <i>KRAS</i> MutationPasi A Jänne, Gregory J Riely, Shirish M Gadgeel, et al.
Cancer Discovery|December 6, 2022
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic CancerSamantha B Kemp, Noah Cheng, Nune Markosyan, et al.
Oncogene|January 24, 2012
Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastomaE L Carpenter, E A Haglund, E M Mace, et al.
Science Signaling|November 13, 2014
Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFRPeter J Belmont, Ping Jiang, Trevor D McKee, et al.
Cancer Research|September 20, 2023
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor EfficacySuman Mukhopadhyay, Hsin-Yi Huang, Ziyan Lin, et al.
Pageof 51

Showing results (481-490 of 510) with videos related to

Sort By:
Pageof 51
Science Translational Medicine|March 25, 2011
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsLecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, et al.
The New England Journal of Medicine|June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Mark M Awad, Ryohei Katayama, Michele McTigue, et al.
Journal of Medicinal Chemistry|January 18, 2022
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i>-Deleted CancersChristopher R Smith, Ruth Aranda, Thomas P Bobinski, et al.
The Journal of Antibiotics|October 10, 1998
Discovery of MC-02,331, a new cephalosporin exhibiting potent activity against methicillin-resistant Staphylococcus aureusS J Hecker, I S Cho, T W Glinka, et al.
Cancer Research|July 28, 2011
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitorsTakaaki Sasaki, Jussi Koivunen, Atsuko Ogino, et al.
The New England Journal of Medicine|June 3, 2022
Adagrasib in Non-Small-Cell Lung Cancer Harboring a <i>KRAS</i> MutationPasi A Jänne, Gregory J Riely, Shirish M Gadgeel, et al.
Cancer Discovery|December 6, 2022
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic CancerSamantha B Kemp, Noah Cheng, Nune Markosyan, et al.
Oncogene|January 24, 2012
Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastomaE L Carpenter, E A Haglund, E M Mace, et al.
Science Signaling|November 13, 2014
Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFRPeter J Belmont, Ping Jiang, Trevor D McKee, et al.
Cancer Research|September 20, 2023
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor EfficacySuman Mukhopadhyay, Hsin-Yi Huang, Ziyan Lin, et al.
Pageof 51